After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
EXEL belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Exelixis Inc is $9.80B. A total of 2.83 million shares were traded on the day, compared to an average of 2.29M shares.
In the most recent transaction, Freire Maria C bought 44,114 shares of EXEL for 34.94 per share on Feb 14 ’25. In a previous transaction on Feb 14 ’25, Beckerle Mary C bought 12,210 shares at 34.88 per share.
Among the insiders who bought shares, POSTE GEORGE acquired of 15,874 shares on Feb 14 ’25 at a per-share price of $34.74. In another insider transaction, Eckhardt Sue Gail bought 11,568 shares at $34.37 per share on Feb 14 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, EXEL has a high of $37.59 and a low of $20.14.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. EXEL’s latest balance sheet shows that the firm has $1.47B in Cash & Short Term Investments as of fiscal 2021. There were $51.27M in debt and $337.59M in liabilities at the time. Its Book Value Per Share was $7.97, while its Total Shareholder’s Equity was $2.21B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for EXEL is Buy with a score of 4.05.
